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The Association of Helicobacter Pylon
with Intestinal Type Gastric
Adenocarcinoma in a Hawaii Population*
Hausen Cheong MD, Patti Char MS, Yuan Chang MS, Stanley S. Shimoda MD
American-Japanese Th Ha wall with gastric cancer have character
istics intermediate to those in Japan and the maTh/and United States.
Japanese and maThiand U.S. studies have found Helicobacter
pylon is associated with intestinal type gastric adenocarcinoma.
The present Hawaii study confirmed this association which is
independent of Japanese race (27.6% intestinal type and 4.5%
diffuse type were H. pylon/positive, p=0. 031, n=80).
Introduction
Recent studies have found an association between H. pylon and
gastric neoplasm.1’2Ninety-five percent of gastric neoplasms are
adenocarcinomas.3There are two subtypes of gastric adenocarcino
mas, the diffuse type and the intestinal type. Intestinal type ofgastric
adenocarcinomas have goblet cells within the neoplastic tissue and
have a better prognosis.4These histological subsets were studied
specifically by Parsonnet, et al, who discovered that H. pylon was
present in 89% of intestinal type cases compared with only 32% of
diffuse type cases.56Recently, Parsonnet’ s findings were confirmed
in Japan by Endo, et al, who found that 82% of 34 patients with
intestinal type gastric cancer had H. pylon compared with 29% of21
patients with diffuse type.7 The purpose of this study was to verify
the association between H. pylon and intestinal type gastric adeno
carcinoma in a Hawaii study population that includes a sizable
subpopulation of American-Japanese who are known to have an
incidence of gastric cancer intermediate to the native Japanese and
mainland U.S. study populations.
* Division of Gastroenterology
Department of Internal Medicine
John A. Bums School of Medicine
University of Hawaii at Manoa
Kaiser Permanente Hospital
Moanalua
Kuakini Medical Center
Address Reprint Request to:
Stanley S. Shimoda, M.D.,
Division of Gastroenterology,
Department of Internal Medicine
321 North Kuakini St., Suite #503,
Honolulu Hawaii 96817
Methods
In a period of 16 months from January 1990 through April 1991,
80 patients with gastric adenocarcinoma were identified through the
tumor registries at two Honolulu hospitals, Kaiser Permanente and
Kuakini Medical Center. The registries also provided information
regarding age, race and sex of these patients.
Pathology slides stained with hematoxylin and eosin (H&E) from
the 80 gastric adenocarcinoma cases were examined blindly by one
of two examiners (Y.C.). Each patient’s set of slides were examined
by light microscopy at 1 OOx magnification over 25 fields which
included both pericancerous non-neoplastic tissue and neoplastic
tissue. The examiner determined the histological type (intestinal or
diffuse) of each case.
The examiner also determined the absence or presence of
H. pylon. A slide positive for H. pylon was defined as the presence
of 5 or more curvilinear bacilli within a single lOOx field. Greater
magnification was used as necessary to help identify the H. pylon
bacilli. This design was selected to reduce false positives. One slide
representative of intestinalization without H. pylon and a second
slide of H. pylon without intestinalization, were inserted with each
set of slides as controls.
All H. pylon positive slides and an equal number of randomly
selected H. pylon negative slides from the same hospital were
identified. These slides were randomized and re-examined by a
second blinded observer using the same technique mentioned above
(H.C.).
Statistical analyses were performed using SPSS (Statistical Pack
age for Social Sciences version 4.2).
Results
Fifty-eight of the 80 adenocarcinoma cases (73%) were of the
intestinal type, while the remaining 22 cases (27%) were of the
diffuse histological type. Table 1 shows that H. pylon was present
in 16 of the 58 intestinal cases (27.6%) compared with only one of
the 22 diffuse cases (4.5%), a difference which was statistically
significant (Fisher’s exact test: p=O.O3l).
A comparison of cases with and without H. pylon by age, gender,
hospital site and Japanese race is presented in Table 2. None of the
comparisons was statistically significant.
The reexamination by a second blinded examiner of 17 H. pylon
positive cases and 17 randomly selected negative cases, stratified by
hospital, showed complete agreement between the two observers.
This resulted in a Cohen’s kappa coefficient of 1.00 (p <0.001).
Controls were correctly identified 100% of the time in both the
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Table 1.—The Relationship of Helicobacter pylon to Gastric
Adenocarcinoma
original trial and the validity trial.
Histological Type
Discussion
The present study found a statistically significant relationship
between H. pylon and intestinal type gastric adenocarcinoma which
is consistent with previous studies.57 The study’s stringent criteria
for H. pylon positivity resulted in a prevalence less than that of
previous reports. In contrast to previous studies, no significant
relationship between age and H. pylon was found using cutoffs of
50, 55, 60, 65 and 70 years of age.2 This result may be due to the
preponderance of subjects similar in age; 88% of the study popula
tion was 60+ y.o.
This Hawaii study is unique in that it represents an American-
Japanese population with a gastric cancer mortality rate that is in
between those of Japan and the mainland United States. Gastric
cancer is the second leading cause of cancer mortality in Hawaii
among American-Japanese males with an age adjusted mortality
rate of 15.9 per 100,000.8 In Japan, the male age adjusted mortality
rate is 32.8 per 100,000 whereas in the United States this mortality
rate is 5.0 per 100,000. Gastric cancer is the most common cause of
cancer mortality in Japan compared to being the 7th most common
cause of cancer deaths in the United States.9Parsonnet’ s study was
carried out on the West Coast of the United States where there is a
small Japanese population whereas Endo’s study in Japan was of a
Japanese population. American-Japanese comprise 22% ofHawaii’s
population, but 76.3% ofthepresent study’s population. ‘°Parsonnet’ s
and Endo’s results show similar H. pylon prevalence in their study
population despite different Japanese populations which would
suggest that H. pylon positivity was not associated with Japanese
race. This was consistent with the present study which found that
H. pylon positivity was not associated with Japanese race (see Table
2).
Another Hawaii study published by Nomura found the presence
of anti-H. pylon IgG antibodies in 94% of the stored serum samples
belonging to 109 American-Japanese males who developed gastric
carcinoma. This case-control study showed that gastric cancer is
associated with H. pylon in both the intestinal and diffuse sub
groups. Intestinalization was found to be present in 73.0% of
Nomura’s population compared to 72.5% in the present study’s
population. This suggests that the two populations are similar.
Despite having similar American-Japanese populations, it is not
possible to compare Nomura’ s H. pylon antibody study to the
present light microscopy study. The present study detected the
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Table 2.—Helocobacter pylon and Various Characteristics Among
Gastric Adenocarcinoma Cases
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Characteristic Present Absent Ratio Limit
Histology
__________ ________ ______________
Intestinal_type
____ __ _____
Diffuse type
Hospital
Kuakini
Kaiser
Age (years)
_____
>60
60
Gender
female
male
Race
Japanese
Non-Japanese
*
= Referent Group
47
16
presence ofH. pylon by biopsy at the time ofdiscovery of the cancer
whereas the antibody assay for H. pylon only indicates exposure to
this pathogen. In a stored serum study, it is possible to miss cases of
H. pylon associated with gastric cancer if infection occurred after
the serum was drawn. The average time between phlebotomy and
cancer diagnosis was 13 years in the stored serum study. Another
problem is that antibody titers may also become negative ifH. pylon
disappeared more than 1 year prior to sampling. On the other hand,
in a light microscopy study, it is possible to miss cases of H. pylon
associated with cancer where the pathogen disappeared after the
cancer developed or where an inadequate stain is used. The neoplas
tic tissue, especially of the diffuse type, may present an environment
hostile to H. pylon growth.’
In summary, this Hawaii study confirms the relationship between
H. pylon and intestinal type gastric adenocarcinoma as found in
studies in Japan and the mainland United States. The association
between H. pylon and intestinal type adenocarcinoma was not
affected by age, gender, institution, or Japanese race.
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Intestinal Type Diffuse Type
# of cases (%) # of cases (%)
H. pylon Present 16 (27.6%) 1 (4.5%)
H. pylon Absent , 42 (72.4%) 21(95.5%)
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